Rates of SCD* and CDAI category
| CDAI | SCD | |
|---|---|---|
| n | Rates | |
| Remission | 8,962 | 273 (3.1%) |
| Low | 1,1871 | 926 (7.8%) |
| Moderate | 8,104 | 1,059 (13.1%) |
| High | 4,600 | 783 (17.0%) |
| Overall | 33,537 | 3,041 (9.1%) |
LDA: 2.8 < CDAI ≤ 10; moderate disease activity: 10 < CDAI ≤ 22; high disease activity: CDAI > 22. * SCD determined with patient self-report of difficulty thinking and confusion
The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100725_sup_1.pdf.
The authors would like to thank all the participating investigators and patients in the CorEvitas Rheumatoid Arthritis Registry who contributed data for this study.
OP, DAP, and JMK equally contributed to: Conceptualization, Data curation, Formal analysis, Writing—original draft, Writing—review & editing, Supervision. GR: Conceptualization, Formal analysis, Writing—original draft, Writing—review & editing, Supervision. LRH: Conceptualization, Data curation, Writing—original draft, Writing—review & editing, Supervision.
DAP has equity interests and is an employee of CorEvitas (formerly known as Corrona), is a member of the Board of Directors of the Corrona Research Foundation (CRF), and has received honoraria/consulting fees from Novartis, Sanofi, Genentech, Roche, and Abbvie. GR is a consultant for Corrona Research Foundation and CorEvitas, LLC. LRH is an employee and stockholder of CorEvitas and has received honoraria/consulting feeds from AbbVie, Bristol-Myers Squibb, and Roche, on the speaker’s bureau for Bristol-Myers Squib, and received grant funding from Pfizer. JMK is the president of the Corrona Research Foundation where he serves in a non-remunerative position. He is also a consultant for CorEvitas.
Sponsor approval and continuing review were obtained through a central IRB (New England Independent Review Board, NEIRB No. 120160610) and complied with the Declaration of Helsinki.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
Data are available from CorEvitas, LLC through a commercial subscription agreement and are not publicly available. Additional aggregated data are available from the authors.
This study was funded by the Corrona Research Foundation. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2023.